Scientists find a way to break pancreatic cancer’s protective shield
Scientists at the University of Miami have identified a method to weaken pancreatic cancer's defenses by targeting the IL1RAP receptor. This discovery is moving toward a clinical trial combining targeted therapy with chemoimmunotherapy.
Why it matters
Offers a potential breakthrough in treating one of the most lethal forms of cancer by disrupting the tumor's supportive microenvironment.
Researchers have identified a promising way to weaken one of pancreatic cancer's key defenses against treatment. The approach focuses on blocking IL1RAP, a receptor that plays a central role in inflammatory signaling and helps coordinate the network of cells surrounding pancreatic tumors.
The work, led by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, is now moving toward a first-of-its-kind neoadjuvant clinical trial. The planned trial will combine IL1RAP targeted therapy with chemoimmunotherapy in patients with operable pancreatic cancer before surgery.
Why Pancreatic Cancer Is So Hard To Treat
Pancreatic cancer remains among the most challenging cancers to treat successfully. One major obstacle is the tumor microenvironment, the complex community of cells and structural tissue surrounding a tumor that can help cancer survive and resist therapy.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in